These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 25913065)
1. The aging prostate is never "normal": implications from the genomic characterization of multifocal prostate cancers. Schlomm T; Weischenfeldt J; Korbel J; Sauter G Eur Urol; 2015 Sep; 68(3):348-50. PubMed ID: 25913065 [TBL] [Abstract][Full Text] [Related]
2. [Molecular pathology of multifocal prostate cancer and its clinical application]. Cheng L; Teng XD; Zhou J Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):436-9. PubMed ID: 22088367 [No Abstract] [Full Text] [Related]
3. Genomic and phenotypic heterogeneity in prostate cancer. Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650 [TBL] [Abstract][Full Text] [Related]
4. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350 [TBL] [Abstract][Full Text] [Related]
5. Distinguishing indolent from aggressive prostate cancer. Culig Z Recent Results Cancer Res; 2014; 202():141-7. PubMed ID: 24531788 [TBL] [Abstract][Full Text] [Related]
6. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228 [TBL] [Abstract][Full Text] [Related]
7. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398 [TBL] [Abstract][Full Text] [Related]
8. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Hermans KG; Bressers AA; van der Korput HA; Dits NF; Jenster G; Trapman J Cancer Res; 2008 May; 68(9):3094-8. PubMed ID: 18451133 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer: Multifocal disease--independent clonal lineages in malignant nodules and even in normal tissue. Thoma C Nat Rev Urol; 2015 Apr; 12(4):177. PubMed ID: 25782174 [No Abstract] [Full Text] [Related]
17. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Shah RB Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797 [TBL] [Abstract][Full Text] [Related]
18. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811 [TBL] [Abstract][Full Text] [Related]
19. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. Singh A; Jones RF; Friedman H; Hathir S; Soos G; Zabo A; Haas GP Anticancer Res; 1999; 19(6B):5415-7. PubMed ID: 10697570 [TBL] [Abstract][Full Text] [Related]